Advanced Medical Specialties

Miami, Florida 33176

0 studies enrolling now · 29 studies all time

What they study most

Advanced Prostate Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Non-Small Cell Lung, Chronic Myelogenous Leukemia in Chronic Phase, Chronic Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Fallopian Tube Cancer, Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Kidney Neoplasms

Studies at this site

• Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC — Completed
• Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer — Completed
• The BEACON Study (Breast Cancer Outcomes With NKTR-102) — Completed
• A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer — Stopped early
• Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer — Completed
• Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC — NO_LONGER_AVAILABLE
• A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer — Completed
• Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer — Stopped early
• A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread — Completed
• AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy — Completed
• A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer — Completed
• TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy — Stopped early
• A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy — Stopped early
• A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment — Completed
• Phase 1 and 2 Study of PX-866 and Cetuximab — Completed
• Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer — Completed
• Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer — Completed
• Pre-op Rectal ChemoRad +/- Cetuximab — Completed
• Gemzar, Cisp, Sunitinib Urothelial Ca — Completed
• CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib — Completed
• First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy — Completed
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors — Completed
• Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma — Stopped early
• Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer — Completed
• Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer — Stopped early
• Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma — Stopped early
• Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients — Completed
• Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia — NO_LONGER_AVAILABLE
• A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Stopped early